PURPOSE Unlike the normal organ segmentation task, automatic tumor segmentation is a more challenging task because of the existence of similar visual characteristics between tumors and their surroundings, especially on computed tomography (CT) images with severe low contrast resolution, as well as the diversity and individual characteristics of data acquisition procedures and devices. Consequently, most of the recently proposed methods have become increasingly difficult to be applied on a different tumor dataset with good results, and moreover, some tumor segmentors usually fail to generalize beyond those datasets and modalities used in their original evaluation experiments. METHODS In order to alleviate some of the problems with the recently proposed methods, we propose a novel unified and end-to-end adversarial learning framework for automatic segmentation of any kinds of tumors from CT scans, called CTumorGAN, consisting of a Generator network and a Discriminator network. Specifically, the Generator attempmor segmentation. CONCLUSION In order to overcome those key challenges arising from CT datasets and solve some of the main problems existing in the current deep learning-based methods, we propose a novel unified CTumorGAN framework, which can be effectively generalized to address any kinds of tumor datasets with superior performance.PURPOSE The phase Ib/II open-label study (NCT01992653) evaluated the antibody-drug conjugate polatuzumab vedotin (pola) plus rituximab/obinutuzumab, cyclophosphamide, doxorubicin, and prednisone (R/G-CHP) as first-line therapy for B-cell non-Hodgkin lymphoma (B-NHL). We report the pharmacokinetics (PK) and drug-drug interaction (DDI) for pola. METHODS Six or eight cycles of pola 1.0-1.8 mg/kg were administered intravenously every 3 weeks (q3w) with R/G-CHP. Exposures of pola [including antibody-conjugated monomethyl auristatin E (acMMAE) and unconjugated MMAE] and R/G-CHP were assessed by non-compartmental analysis and/or descriptive statistics with cross-cycle comparisons to cycle 1 and/or after multiple cycles. Pola was evaluated as a potential victim and perpetrator of a PK drug-drug interaction with R/G-CHP. Population PK (popPK) analysis assessed the impact of prior treatment status (naïve vs. relapsed/refractory) on pola PK. RESULTS Pola PK was similar between treatment arms and independent of line of therapy. Pola PK was dose proportional from 1.0 to 1.8 mg/kg with R/G-CHP. Geometric mean volume of distribution and clearance of acMMAE ranged from 57.3 to 95.6 mL/kg and 12.7 to 18.2 mL/kg/day, respectively. acMMAE exhibited multi-exponential decay (elimination half-life ~ 1 week). Unconjugated MMAE exhibited formation rate-limited kinetics. Exposures of pola with R/G-CHP were similar to those in the absence of CHP; exposures of R/G-CHP in the presence of pola were comparable to those in the absence of pola. CONCLUSIONS Pola PK was well characterized with no clinically meaningful DDIs with R/G-CHP. Findings are consistent with previous studies of pola + R/G, and support pola + R/G-CHP use in previously untreated diffuse large B-cell lymphoma.The liposome-based biosensors are used for detection of nucleic acids and proteins as organic beds which are biocompatible tools for point of care tests, but their lack of sensitivity has been challenging. Therefore, designing a proper strategy is vital to increase the sensitivity of the target in diagnostic tests. In this study, for the first time, we use a combination of cationic DOPC liposome (dioleoylphosphatidylcholine) with MoS2 to enhance the sensitivity of liposomal sensors clearly. The electrochemical measurements are performed between potentials at - 0.4 V and + 0.4 V with 1 mM [Fe(CN)6]-3/-4. At first, we construct the DOPC/MoS2 hybrid (as a mineral/organic bed) to promote higher electrochemical behavior than DOPC liposome (as organic bed). In this research, adding AuNP can cause attachment with both the DOPC and MoS2. Therefore, the electrochemical reactions are enhanced accordingly to provide more positions for attaching the probes on the AuNP.  https://www.selleckchem.com/products/bpv-hopic.html  So our DOPC-MoS2/AuNP hybrid can detect miR-21 with high sensitivity (LOD = 10 aM) because of attachment of miR-21 to MoS2/AuNP in addition to DOPC/AuNP. This sensor has also high specificity and repeatability as a biocompatible sensor, which can be used in point of care tests and transduction instruments.Several studies have shown the efficacy of statins for some autoimmune disorders caused by anti-inflammatory and immunomodulatory reactions. However, little information is available about the impact of statins on relapse in antineutrophil cytoplasmic antibody-associated vasculitis (AAV). We performed the first investigation examining whether statin use has an effect on suppressing the first relapse of AAV in Japanese patients with AAV. This single-center retrospective cohort study included 98 consecutive patients with newly diagnosed AAV from Aichi Medical University Hospital, Japan between March 2009 and December 2017. Time to first relapse from the first remission was compared between 36 patients in the statin group and 62 patients in the non-statin group using multivariate Cox proportional hazard models, which were adjusted for clinically relevant factors. During the follow-up period (median, 24 months; interquartile range, 9-50 months), 35 (97.2%) patients in the statin group achieved remission, whereas 56 (90.3%) patients achieved remission in the non-statin group (P = 0.201). After achieving the first remission, 9 (25.7%) patients in the statin group and 29 (51.8%) patients in the non-statin group had at least one relapse. Multivariate Cox proportional hazard models revealed that statin use was significantly associated with a lower incidence of relapse compared with non-statin use (multivariate-adjusted hazard ratio = 0.41, 95% confidence interval 0.18-0.92; P = 0.031). Patients with statin use were associated with a lower incidence of relapse in AAV. Our results should be assessed in well-designed randomized controlled trials.Idiopathic inflammatory myopathies (IIM) are rare connective tissue diseases, which can lead to internal organ involvement. IL-33/ST2 pathway is involved in the pathogenesis of numerous diseases including autoimmune disorders. IL-33 fulfils cardioprotective function, while soluble ST2 (sST2) is a decoy receptor that reduces protective impact of IL-33. The aim of the study was to evaluate the concentrations of sST2 and IL-33 in sera of patients with IIM and evaluate its associations with the clinical course of the disease. Patients with IIM as well as age- and sex-matched healthy controls were recruited. Concentrations of sST2 and IL-33 were assessed with ELISA in sera of both patients and controls. Patients were asked to fill in the questionnaires concerning clinical symptoms and physical functioning. Concentrations of sST2 and IL-33 were correlated with the results of laboratory tests and clinical symptoms. Concentrations of sST2 were significantly higher in IIM group than in healthy subjects (median sST2 in IIM 26.